Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Becton Dickinson

BDX Healthcare Unknown Updated August 01, 2026
$165.67
52W $127.59 – $187.35
53/100
$60.00B
41.9
0.27
AI Committee Verdict
Watch
Conviction: Contested · 50% agreement · 6 analysts
+17.9%
-1.3%
13.42:1
Contested

Is BDX Bullish or Bearish?

Mixed. Innellis AI committee rates Becton Dickinson (BDX) Watch with a composite score of 53/100 , based on 6 analysts with 50% agreement. Last updated August 01, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.56 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.44 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — market regime is bullish (bull market -- normal position sizing). Value Analyst remains cautious — p/e of 40.1 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 2.5% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.20 across 18 articles, 14d) — News
Bear Case
  • P/E of 40.1 is expensive by classic value standards — Value
  • ROE of only 4.5% -- cheap may mean cheap for a reason — Value
  • EPS declining -24.8% YoY despite any revenue growth — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 01, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 78%
of 93 Healthcare peers
Value Analyst bearish
35 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 2.5% pays you to wait
− P/E of 40.1 is expensive by classic value standards
Growth Analyst neutral
48 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -24.8% YoY despite any revenue growth
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 18 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.5 to 53.4.

Analyst-level changes:
  • Macro Analyst: stance neutral->bullish; score 58->70 (+12).
  • Portfolio Manager: +2 bearish signal(s).
  • Value Analyst: stance neutral->bearish; score 42->35 (-7); +1 bearish signal(s).

Comparing 2026-07-31 to 2026-08-01 (1 day apart).

Technical Analysis

RSI (14)
68.2
Neutral
MACD Histogram
1.126
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$163.46
Resistance
$195.24
Bollinger %B
0.89
Inside Bands
Price vs Moving Averages
EMA 9
$161.87 Above
EMA 21
$157.81 Above
EMA 50
$154.70 Above
EMA 200
$167.56 Below

Fundamental Analysis

Valuation
64
Growth
68
Profitability
0
Financial Health
51
Cash Flow
37
Valuation
P/E Ratio 41.9×
P/B Ratio 1.93×
PEG Ratio -1.69
Dividend Yield 0.02%
52W High $187.35
52W Low $127.59
Quality & Growth
ROE 6.6%
ROA 3.0%
Gross Margin 46.5%
Operating Margin 10.6%
Revenue Growth YoY
Debt / Equity 0.72
AI Fundamental Assessment
P/E ratio of 41.9 (rich relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -1.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.5%; Current ratio of 0.94 (tight short-term liquidity); Debt-to-equity of 0.72; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (11.20); Most recent quarter beat estimates by 3.5%; 2 consecutive earnings beats; EPS growth accelerating (-26.5% -> -0.3% QoQ); Analyst estimates falling over recent quarters
Get the Full BDX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore BDX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime